MMAE - CAS 474645-27-7

MMAE - CAS 474645-27-7 Catalog number: BADC-00324

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Monomethyl Auristatin E (MMAE) is a synthetic analog of dolastatin 10 that similarly inhibits tubulin polymerization and exhibits potent cytotoxicity. It is commonly conjugated with monoclonal antibodies directed at antigens specific to cancer cells for tumor-directed cytotoxicity.

General Information

ADCs Cytotoxin
Product Name
Catalog Number
Molecular Formula
Molecular Weight

Chemical Structure

  • MMAE

Ordering Information

Catalog Number Size Price Stock Quantity
BADC-00324 25 mg $298 In stock
Add to cart
≥98.0% (HPLC)
White solid powder
MMAE; Vedotin; Monomethyl auristatin E; (2S)-N-[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide; Monomethyl auristatin E;
Monomethylauristatin E; UNII-V7I58RC5EJ; V7I58RC5EJ; MMAE; 474645-27-7; N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide; 4Q5; MMAE, monomethyl auristatin E; SCHEMBL5402144
Soluble in DMSO, not in water
Dry, dark and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).
ADCs Cytotoxin
-20°C (International: -20°C)
Canonical SMILES
InChI Key
1.An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
Li H1, Yu C2, Jiang J3, Huang C2, Yao X1, Xu Q2, Yu F2, Lou L4, Fang J1,5,6. Cancer Biol Ther. 2016 Apr 2;17(4):346-54. doi: 10.1080/15384047.2016.1139248. Epub 2016 Feb 6.
Antibody-drug conjugate (ADC) is a novel class of therapeutics for cancer target therapy. This study assessed antitumor activity of ADC with an antimitotic agent, monomethyl auristatin E (MMAE) and a humanized monoclonal anti-HER2 antibody, hertuzumab, in gastric cancer. The efficacy of hertuzumab-MC-Val-Cit-PAB-MMAE (hertuzumab-vcMMAE) on human epidermal growth factor receptor 2 (HER2) positive human gastric cancer cells, NCI-N87, was evaluated in vitro and in vivo. The cytotoxicity of hertuzumab was significantly enhanced after conjugation with MMAE. Compared to trastuzumab, hertuzumab had a higher affinity to HER2 and had more potent antibody-dependent cell-mediated cytotoxicity (ADCC) activity in vitro. After conjugation with MMAE, the binding specificity for HER2 was not affected. Furthermore, the internalization of hertuzumab-vcMMAE in HER2 positive gastric cancer cells was verified. Although the conjugation of hertuzumab and MMAE decreased the ADCC effect, the overall cytotoxicity was dramatically increased in HER2 positive gastric cancer cells.

Related Products

Get in Touch

Verification code
Historical Records: DBCO-(PEG)3-VC-PAB-MMAE | Exatecan Mesylate | endo-BCN-PEG4-NHS ester | DBCO-PEG4-vc-PAB-MMAE | DBA-DM4 | MPB-MMAF | 4-Formyl-N-(2-Isopropoxyethyl)benzamide | MC-Val-Cit-PAB-MMAE | Mc-Val-Cit-PABC-PNP | N-Deacetylcolchicine | MMAE
Inquiry Basket